Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | LDHA | P00338 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5159103 | 0.91 | MRGPRX4 (0.43) | KMT2ARAB9ACA12CA2CA9 | |
| SCHEMBL5157449 | 0.91 | HTT (0.41) | KMT2ANPC1RAB9AMEN1CA12 | |
| SCHEMBL5158374 | 0.91 | DRD2 (0.42) | KMT2ANPC1RAB9AMEN1DRD2 | |
| SCHEMBL5157693 | 0.89 | NPC1 (0.38) | KMT2ANPC1RAB9AMEN1SMN1; SMN2 | |
| SCHEMBL5155145 | 0.87 | CYP2B6 (0.39) | KMT2AMEN1CA12CA2CA9 | |
| SCHEMBL6816997 | 0.84 | ALDH1A1 (0.47) | CA12CA2CA9SMN1; SMN2MAPT | |
| SCHEMBL14621031 | 0.82 | NPC1 (0.37) | KMT2ANPC1RAB9AMEN1SMN1; SMN2 | |
| SCHEMBL5155175 | 0.82 | HTT (0.40) | KMT2ANPC1RAB9AMEN1SMN1; SMN2 | |
| SCHEMBL5157597 | 0.82 | MRGPRX4 (0.41) | KMT2ANPC1RAB9AMEN1GAA | |
| SCHEMBL5157674 | 0.81 | TRPM8 (0.42) | KMT2AMEN1MAPTLDHAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7189873-B2 | Propargylether derivatives, a process for their preparation and their use for controlling phytopathogenic microorganisms | SYNGENTA CORP PROTECTION, INC. (US) | 2007-03-13 | — | — | US | claimed |
| EP-1549609-B1 | PROPARGYLETHER DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR USE FOR CONTROLLING PHYTOPATHOGENIC MICROORGANISMS | SYNGENTA PARTICIPATIONS AG (CH) | 2007-01-24 | — | — | EP | claimed |
| US-20060167316-A1 | Propargylether derivatives, a process for their preparation and their use for controlling phytopathogenic microorganisms | SYNGENTA CROP PROTECTION, INC. | 2006-07-27 | — | — | US | claimed |
| EP-1549609-A2 | PROPARGYLETHER DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR USE FOR CONTROLLING PHYTOPATHOGENIC MICROORGANISMS | Syngenta Participations AG (CH) | 2005-07-06 | — | — | EP | claimed |
| WO-2004033413-A2 | PROPARGYLETHER DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR USE FOR CONTROLLING PHYTOPATHOGENIC MICROORGANISMS | SYNGENTA PARTICIPATIONS AG (CH) | 2004-04-22 | — | — | WO | claimed |
| US-7189873-B2 | Propargylether derivatives, a process for their preparation and their use for controlling phytopathogenic microorganisms | SYNGENTA CORP PROTECTION, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| EP-1549609-B1 | PROPARGYLETHER DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR USE FOR CONTROLLING PHYTOPATHOGENIC MICROORGANISMS | SYNGENTA PARTICIPATIONS AG (CH) | 2007-01-24 | — | — | EP | disclosed |
| US-20060167316-A1 | Propargylether derivatives, a process for their preparation and their use for controlling phytopathogenic microorganisms | SYNGENTA CROP PROTECTION, INC. | 2006-07-27 | — | — | US | disclosed |
| EP-1549609-A2 | PROPARGYLETHER DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR USE FOR CONTROLLING PHYTOPATHOGENIC MICROORGANISMS | Syngenta Participations AG (CH) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004033413-A2 | PROPARGYLETHER DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR USE FOR CONTROLLING PHYTOPATHOGENIC MICROORGANISMS | SYNGENTA PARTICIPATIONS AG (CH) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167316-A1 | Propargylether derivatives, a process for their preparation and their use for controlling phytopathogenic microorganisms | GRHPR, CBR3, CYP8B1 | KMT2A 3559/4885NPC1 3897/4885RAB9A 1930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.